Press Releases
Nov 16, 2023

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer TOKYO and NEW YORK

Nov 16, 2023

- Accelerating the development of the life science ecosystem centered on Tsukuba - - Promoting innovative drug discovery research using AI and digital technologies and creating new drug discovery...

Nov 15, 2023

- Acquire PRL-02, prostate cancer treatment program being developed by Propella Therapeutics - TOKYO and PITTSBORO, N.C., Nov. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President...


Oct 10, 2023

Astellas ranked in Seramount’s 2023 “100 Best Companies” list for the ninth consecutive year This year, Astellas once again was named as a top company for working parents on Seramount’s...

Oct 10, 2023

Astellas was once again ranked in Seramount’s 2023 list of 100 Best Companies confirming our commitment to creating a supportive workplace for working parents. This year, Astellas is proud to...

Oct 2, 2023

Astellas reflects on the importance of engagement, diversity, equity and inclusion in fostering a people-centric culture. Astellas is proud to celebrate Global Diversity Awareness Month this...


Stay Connected

Get only the email alerts you want.


Media Contacts


For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.


Astellas on Twitter
Download Fact Sheet
Explore U.S. Products